Sign In
Buy EQ
$3.11
+0.320 (+11.47%)
At Close: Jun 03, 2026
Equillium to Present at Investor Conferences in November 2020
08:35am, Tuesday, 10'th Nov 2020
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
08:35am, Friday, 06'th Nov 2020
100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date
Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis
EQ Stock: 6 Things to Know about Biotech Company Equillium
11:33am, Friday, 30'th Oct 2020
Equillium (EQ) stock is seeing gains on Friday after getting the go-ahead from the FDA for a drug trial treating the coronavirus. The post EQ Stock: 6 Things to Know about Biotech Company Equillium ap
What This FDA Update Means for Equillium's COVID-19 Study
10:36am, Friday, 30'th Oct 2020
Equillium Inc. (NASDAQ: EQ) shares jumped on Friday after the company announced a key update from the U.S.
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
04:13pm, Thursday, 29'th Oct 2020
Equillium p lans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Equillium Announces Closing of Public Offering of Common Stock
08:05pm, Tuesday, 18'th Aug 2020
LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium Announces Pricing of Public Offering of Common Stock
01:42am, Friday, 14'th Aug 2020
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium Announces Proposed Public Offering of Common Stock
08:02pm, Thursday, 13'th Aug 2020
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
12:37pm, Wednesday, 12'th Aug 2020
LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) * Allovir Inc (NASDAQ: ALVR) * BioLife Solutions Inc (NASDAQ: BLFS) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) (reacted to sec
What Type Of Shareholders Make Up Equillium, Inc.'s (NASDAQ:EQ) Share Registry?
12:00pm, Tuesday, 11'th Aug 2020
If you want to know who really controls Equillium, Inc. (NASDAQ:EQ), then you'll have to look at the makeup of its...
What Type Of Shareholders Own The Most Number of Equillium, Inc. (NASDAQ:EQ) Shares?
11:51am, Tuesday, 11'th Aug 2020
A look at the shareholders of Equillium, Inc. (NASDAQ:EQ) can tell us which group is most powerful. Institutions will...
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
08:07pm, Monday, 10'th Aug 2020
Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDALA JOLLA, Calif., Aug. 10, 2020 (GLOBE NEWSWIR
